Warnock DG - Search Results

1

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.

Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F. Barrera-Chimal J, et al. Among authors: warnock dg. J Am Soc Nephrol. 2016 Feb;27(2):398-404. doi: 10.1681/ASN.2014121216. Epub 2015 Sep 11. J Am Soc Nephrol. 2016. PMID: 26361797 Free PMC article.

2

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

Bertocchio JP, Warnock DG, Jaisser F. Bertocchio JP, et al. Among authors: warnock dg. Kidney Int. 2011 May;79(10):1051-60. doi: 10.1038/ki.2011.48. Epub 2011 Mar 16. Kidney Int. 2011. PMID: 21412221 Free article. Review.

3

Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells.

Warnock DG, Kusche-Vihrog K, Tarjus A, Sheng S, Oberleithner H, Kleyman TR, Jaisser F. Warnock DG, et al. Nat Rev Nephrol. 2014 Mar;10(3):146-57. doi: 10.1038/nrneph.2013.275. Epub 2014 Jan 14. Nat Rev Nephrol. 2014. PMID: 24419567 Free PMC article. Review.

4

Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Amador CA, Bertocchio JP, Andre-Gregoire G, Placier S, Duong Van Huyen JP, El Moghrabi S, Berger S, Warnock DG, Chatziantoniou C, Jaffe IZ, Rieu P, Jaisser F. Amador CA, et al. Among authors: warnock dg. Kidney Int. 2016 Feb;89(2):354-62. doi: 10.1038/ki.2015.312. Kidney Int. 2016. PMID: 26422501 Free PMC article.

5

Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

Nguyen Dinh Cat A, Escoubet B, Agrapart V, Griol-Charhbili V, Schoeb T, Feng W, Jaimes E, Warnock DG, Jaisser F. Nguyen Dinh Cat A, et al. Among authors: warnock dg. PLoS One. 2012;7(5):e33743. doi: 10.1371/journal.pone.0033743. Epub 2012 May 4. PLoS One. 2012. PMID: 22574107 Free PMC article.

6

Mineralocorticoid receptor blockers and chronic kidney disease.

Jain G, Campbell RC, Warnock DG. Jain G, et al. Among authors: warnock dg. Clin J Am Soc Nephrol. 2009 Oct;4(10):1685-91. doi: 10.2215/CJN.01340209. Epub 2009 Sep 3. Clin J Am Soc Nephrol. 2009. PMID: 19729430 Review.

7

Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients.

Gaston RS, Schlessinger SD, Sanders PW, Barker CV, Curtis JJ, Warnock DG. Gaston RS, et al. Among authors: warnock dg. J Am Soc Nephrol. 1995 Jan;5(7):1426-33. doi: 10.1681/ASN.V571426. J Am Soc Nephrol. 1995. PMID: 7703380

8

Fabry disease: dose matters.

Warnock DG, Mauer M. Warnock DG, et al. J Am Soc Nephrol. 2014 Apr;25(4):653-5. doi: 10.1681/ASN.2013121322. Epub 2014 Feb 20. J Am Soc Nephrol. 2014. PMID: 24556355 Free PMC article. No abstract available.

9

Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

Tahir H, Jackson LL, Warnock DG. Tahir H, et al. Among authors: warnock dg. J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26. J Am Soc Nephrol. 2007. PMID: 17656478 Clinical Trial.

10

The Furosemide Stress Test and Predicting AKI Outcomes.

Powell TC, Warnock DG. Powell TC, et al. Among authors: warnock dg. J Am Soc Nephrol. 2015 Aug;26(8):1762-4. doi: 10.1681/ASN.2014121160. Epub 2015 Feb 5. J Am Soc Nephrol. 2015. PMID: 25655066 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page